Blood Test Using Platelet Proteins to Detect Prostate Cancer
Tests a platelet protein blood test in men evaluated for suspected prostate cancer.
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Registry title
- Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 11 Mar 2026
- Expected to end
- 30 Sept 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- HeLP TM
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 40 or older who are being seen because doctors suspect prostate cancer. It tests a new blood test based on platelet proteins.
- Age
- 40 years or older
- Sex
- Men only
- Disease stage
- Suspected prostate cancer, not yet diagnosed or treated
- Earlier treatment
- Must not have had treatment for prostate cancer before. Must not have taken blood thinners or antiplatelet drugs such as aspirin or NSAIDs in the 7 days before the blood draw.
Main reasons for not taking part
- Treatment for prostate cancer in the past
- Earlier diagnosis of prostate cancer
- Severe, irreversible coagulopathy (a serious blood clotting problem)
- Taking anticoagulant (blood thinner) therapy
- Aspirin, NSAIDs or other antiplatelet drugs in the 7 days before blood collection
The registry criteria, word for word
Show all 7 criteriaShow less
Who cannot take part
- Men who have previously undergone treatment for prostate cancer
- Men with prior diagnosis of prostate cancer
- Men on anticoagulant therapies or those who have taken antiplatelet agents such as aspirin, NSAIDs (ibuprofen, entrophen, naproxen, diclofenac etc), clopidrogel, prasugrel, ticagrelor, or dipyridamole in the 7 days preceding blood collection
- Men with severe, irreversible coagulopathy
Other criteria
- Eligibility criteria
- Patients ≥ 40 years of age
- All patients with suspicion of PCa; Men ≥ 40 years of age attending Duke Health/Urology with suspicion of prostate cancer (Primary disease) will be approached to consent for the study. Upon consent, samples will be obtained alone, during repeat PSA/other biomarkers testing, or during imaging at Duke Lab
Where in United States
- Duke UniversityDurham, United StatesContact: Judd Moul, MDTaking people
About the trial
What the trial wants to find out
This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease. Currently, doctors rely on multiple tests such as PSA, MRI scans and biopsies to do the same evaluation. Researchers are trying to see if HeLP™ can be a safe and accurate alternative.
Read full original descriptionShow less
The study is inviting men who are being seen for suspicion of prostate cancer (based on symptoms or previous lab results). If they agree to be in the study, the research team will take a sample of their blood at the time they are getting a repeat PSA test or having Imaging. The research test does not affect the care they are already receiving and takes 3 extra tubes of blood (~3 tbsp).
The research team is aiming to include 300 participants total. They believe 278 people are needed to confidently compare results between people with and without prostate cancer.
They will do an interim analysis halfway through the study, once samples from 150 subjects have been collected.
The research is considered low risk-no more uncomfortable or dangerous than a blood draw. There is a risk of loss of privacy, but researchers are taking strong steps to protect privileged information. That includes proper data handling, secure, storage, and making sure the study team is trained in research ethics.
The 2 groups in the trial
- Control Group
Researchers are screening men who are suspicious of Pca, so those who will be negative for cancer will be the control group.
Treatment: HeLP TM
- Case Group
Researchers are screening men who are suspicious of Pca, so those who will be diagnosed will be the case group.
Treatment: HeLP TM
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer: A Prospective Study.
- Plain-language title
- Blood Test Using Platelet Proteins to Detect Prostate CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026